Patent information
IP India · live recordAbstract
The purpose of the present invention is to provide a glucosamine-containing glucan, a modified product of the glucosamine-containing glucan and a conjugate of the glucosamine-containing glucan. This glucosamine-containing glucan is a glucosamine-containing glucan wherein at least one glucosamine residue is bound, by an α-1,4 bond, to each of two or more non-reducing terminals among a plurality of non-reducing terminals of a branched α-1,4 glucan but no glucosamine residue is present at any position other than non-reducing terminals of the branched α-1,4 glucan, and the glucan has a polymerization degree from 15 to 4 × 105 (inclusive). This glucosamine-containing glucan can be provided by having α-glucan phosphorylase act on an aqueous solution that contains a branched α-1,4 glucan and glucosamine-1-phosphate.
Applicants
1Inventors
3Specification
Show full textCollapse
DESCRIPTION TITLE OF THE INVENTION: AMINO SUGAR-CONTAINING GLUCAN, METHOD FOR PRODUCING SAME, AND USE THEREOF 5 TECHNICAL FIELD
[0001] The present invention relates to a glucan having at least one (preferably two or more) aminomonosaccharide residue on each of at least one non-reducing end, a modified 10 product and a conjugate thereof, as well as a method for producing the same, and utilization of the same. More preferably, the present invention relates to a glucan having at least one (preferably two or more) glucosamine residue on each of at least one non-reducing end, a modified product 15 and a conjugate thereof, as well as a method for producing the same, and utilization of the same. The glucan, a modified product and a conjugate thereof of the present invention can have a function to non-covalently bond to a nucleic acid to increase the apparent molecular weight of the nucleic 20 acid. BACKGROUND ART
[0002] A medically effective ingredient of medicaments is rapidly changing from a chemically synthesized stable 25 low-molecular weight compound to an unstable substance which is easily degraded in blood, such as a protein, an antibody and a nucleic acid. For this reason, there is a necessity of stabilizing these unstable medically effective ingredients to keep the blood concentration of the medically 30 effective ingredient high for an elongated time. In addition, in order to decrease side effects of drugs, a necessity of delivering drugs to a target tissue efficiently has been increasing. Under such a background, a so-called drug EG037PCT delivery system (DDS) technique has been utilized in earnest (Non-Patent Documents 1 to 4). A DDS technique refers to a technique and a system for allowing a medically effective ingredient to act on "a required site" at "a required amount" for "a required period of time", that is, controlling 5 ng it with an ideal pharmacokinetics for a drug to maximally exert the effect.
[0003] In the DDS technique, a modifying material for a medically effective ingredient is important. The term 10 "modifying material for a medically effective ingredient" in the present specification refers to a material which modifies a medically effective ingredient by covalently binding, or via non-covalent type interaction, with a medically effective ingredient. By utilizing the modifying 15 material, a variety of properties (for example, pharmacokinetics (for example, absorption, distribution, metabolism and excretion), pharmacological effect, stability and the like) of the medically effective ingredient can be modified. As a substance which has been used 20 previously as the modifying material for the medically effective ingredient, there are a variety of substances, most generally it is a macromolecular material. For example, polyethylene glycol (PEG) which is a synthetic macromolecule, and derivatives thereof are widely utilized as a modifying 25 material for medically effective ingredients. Many medically effective ingredient-modifying materials having a functional group for binding the medically effective ingredient on a terminus of a PEG chain have been developed, and such modifying materials are actually utilized in 30 producing a medicament. Specific application examples include pegylated interferon (product name: PEGASYS). Since interferon has a small molecular weight and is easily excreted into urine, there was a problem that it has a short EG037PCT half-life in blood. However, the half-life in blood was successfully enhanced dramatically by covalently binding interferon to a PEG chain having a molecular weight of 40,000 to form an interferon -conjugate having a high molecular weight. As described above, the remarkable 5 effect is recognized in the modification of the medically effective ingredient or the nanoparticulate carrier for DDSs, with a macromolecular material.
[0004] However, on the other hand, a problem has been pointed 10 out. For example, when a high-molecular weight synthetic macromolecule which has no degradability in a living body and will not undergo renal glomerular filtration is administered to blood, there is a risk that the macromolecule is accumulated in a particular organ and a risk that side 15 effects due to the accumulation are generated. The reason is that a molecule having a molecular weight of a few tens thousands or less present in blood, undergoes renal glomerular filtration and is rapidly excreted into urine, but a molecule having a molecular weight of a few tens thousands 20 or more does not undergo renal glomerular filtration and its excretion into urine is limited. For this reason, a modifying material of the medically effective ingredient which can be safely utilized is expected.
[0005] In addition, when PEG is utilized as a carrier, PEG 25 is usually linked to a medically effective ingredient through a covalent bond. While a covalent bond is excellent in stability, since a portion of the structure of the medically effective ingredient changes, there is a problem that the physiological activity of the medically effective ingredient 30 changes. In addition, when the medically effective ingredient has a plurality of functional groups, there is a problem that groups having different binding position and binding number of PEG chains are synthesized. Such problems EG037PCT become fatal problem in a biomedicine, especially in a proteinaceous medicament and a peptidic medicament. The reason is that it is very difficult to produce products of the same quality reproducibly. Chemical creativity and 5 originality are needed to covalently bind a PEG molecule to a specific amino acid residue, and there are various problems that a specific amino acid sequence may be required, the kind of the medically effective ingredient may be limited, and the like. 10 [0006] On the other hand, the development of a nucleic acid medicament such as an siRNA and an RNA aptamer has been progressing in recent years. Since a DNA and an RNA, which are components of a nucleic acid medicament, are easily degraded by DNA degrading enzyme and RNA degrading enzyme, 15 respectively, it is required to prevent degradation using a suitable carrier. In addition, in the case of a nucleic acid medicament comprising a low-molecular weight nucleic acid medically effective ingredient, it is required to bind it with a macromolecular carrier to extend the blood retention 20 time. Further, it is preferable that these macromolecular carriers for a nucleic acid can be given a targeting function, if necessary. A macromolecular carrier which is safe and has nucleic acid binding property and can solve such problems has been sought. 25 [0007] Polysaccharides have been used as a food raw material for a long time and, in recent years, have begun to be paid attention as a macromolecular material which is environment friendly, as a safe material having biocompatibility and, further, as a functional material. The naturally occurring 30 polysaccharides can be classified into neutral polysaccharides typified by a starch, cellulose, and dextrin; and acidic polysaccharides typified by alginic acid and hyaluronic acid. On the other hand, basic polysaccharides EG037PCT do not occur naturally. A method for producing basic polysaccharides artificially includes a method by which chitin, a naturally derived polysaccharide which is a homopolymer of N-acetylglucosamine, is chemically deacetylated. Such 5 a polysaccharide is generally referred to as chitosan, which is the only basic polysaccharide which is industrially applicable.
[0008] Chitosan has many amino groups in the molecule, and strongly binds to a nucleic acid to form a very huge 10 chitosan:nucleic acid associate referred to as polyplex. There is a problem that such a bond between a polyanion and a polycation is so strong that the dissociation of them is difficult.
[0009] Chitosan is produced by a method such as boiling 15 chitin in a concentrated alkali solution to convert the acetamide group on the carbon at 2-position in a chitin backbone into a free primary amino group. In this method, however, chitosan is degraded into molecules having lower molecular weight by the cleavage of the chitin main chain, 20 and the strict control of a complete deacetylation is difficult, therefore, a polysaccharide wherein a plurality of glucosamines and N-acetylglucosamines are randomly arranged. The number of glucosamines in this polysaccharide molecule cannot be controlled strictly. In addition, in this 25 method, it is not possible to selectively deacetylate only the non-reducing ends of this polysaccharide to produce a polysaccharide wherein glucosamines are bound only to non-reducing ends. That is, in this method, it is not possible to control the strength and ease of dissociation 30 of the bond between chitosan and a nucleic acid. In addition, chitin and chitosan cannot be degraded rapidly in a body. Therefore, chitin and chitosan, which have molecular weights not less than the fractionation size of renal glomerular EG037PCT filtration, have a risk of accumulating in a body. As described above, while chitosan, which is the only cationic polysaccharide, has nucleic acid binding property, it has a limited utility as a carrier for nucleic acid medicaments.
[0010] An amino sugar-containing glucan wherein 5 amino sugar residues are bound only to the non-reducing ends has not been found in nature. Even using a chemical method, the synthesis of an amino sugar-containing glucan wherein amino sugar residues are bound only to the non-reducing ends is 10 not possible, and the chemical synthesis of an amino sugar-containing glucan wherein amino sugar residues are bound only to the non-reducing ends has not been disclosed. In addition, a polysaccharide wherein the number of the bound amino sugar residues can be strictly controlled is not known. 15 [0011] Non-Patent Document 5 discloses that glucosamine-1-phosphate (GlcN-1-P) can be synthesized by a chemical reduction reaction of 2-azido-2-deoxy-glucopyranosyl-1-phosphate, and that a maltooligosaccharide having a glucosamine residue at the 20 non-reducing end is produced by allowing potato-derived -glucan phosphorylase to act on a mixture of glucosamine-1-phosphate and a maltooligosaccharide. However, Non-Patent Document 5 does not disclose or suggest applying a similar method to a high-molecular weight glucan 25 and a branched glucan. It does not disclose that the number of the glucosamine residues in a glucan molecule can be controlled. Further, it does not disclose or suggest that controlling the number of the glucosamine residue in a glucan molecule has an important effect on the strength and form 30 of the bond with a negatively-charged substance such as a nucleic acid. Non-Patent Document 5 does not suggest or disclose that a glucan having one glucosamine residue at the non-reducing end has a binding property to a EG037PCT negatively-charged substance such as a nucleic acid, and that such a glucan has a function to increase the apparent molecular weight of a negatively-charged substance such as a nucleic acid. In addition, when glucosamine-containing glucan 5 is obtained by the method described in Non-Patent Document 5, it is not possible to separate the glucosamine-1-phosphate used in the reaction from the product glucosamine-containing glucan. Since a medicinal material does not allow the mixing of impurities, a 10 glucosamine-containing glucan containing unremoved glucosamine-1-phosphate has a critical drawback of unavailability as a medicament.
Prior Art Documents
15 [Non-Patent Documents]
[0012] [Non-Patent Document 1] Hiroaki Okada, "Drug delivery using functional DDS carriers" Chapter 1, General Statement: Kinousei DDS carrier wo mochiita seizai sekkei ni yoru soyaku 20 (Drug Discovery by Preparation Design Using Functional DDS Carrier), CMC Publishing Co., Ltd., 2008, 1-23 [Non-Patent Document 2] Masayuki Yokoyama, "Polymeric materials for drug carriers, Special Topic, DDS ni riyou sareru kobunshi kagaku (Polymer Chemistry Utilized in DDS)", 25 Drug Delivery System 23-6, 2008: 610-617 [Non-Patent Document 3] Maria Laura Immordino et al., International Journal of Nanomedicine 2006: 1(3) 297-315 [Non-Patent Document 4] J. Milton Harris and Robert B. Chess, NATURE REVIEWS, DRUG DISCOVERY, VOLUME 2, MARCH 2003, 214-221 30 [Non-Patent Document 5] Nawaji et al., Carbohydr. Res. 2008, 343, 2692-2696 SUMMARY OF THE INVENTION EG037PCT PROBLEMS TO BE SOLVED BY THE INVENTION
[0013] The present invention is intended to solve the above-mentioned problems.
[0014] An ideal modifying material for the negatively-charged medically effective ingredient which 5 can be safely utilized is thought to have the following characteristics: (1) The modifying material shall be a macromolecular material which can be degraded in a living body; 10 (2) The modifying material shall have such a stable quality that it can be usable as a medicament. That is, the structure can be specified, and a modifying material having the same quality shall be able to produce every time; (3) The modifying material shall be a macromolecular 15 material which can have the arbitrary number of amino groups which can bind to or interact with a negatively-charged medically effective ingredient at specific sites in the molecule.
[0015] A modifying material for a nucleic acid is thought 20 to be preferable to have the following characteristics: (4) The modifying material shall have a nucleic acid binding property and have a function to increase the apparent molecular weight of the nucleic acid.
[0016] The present inventors thought that a macromolecular 25 substance most excellent as the modifying material for the medically effective ingredient is a glucan (in the present specification, the glucan refers to an -1,4-glucan, and an -1,4-glucan which is branched with an -1,6-bond(s)). Since glycogen or a starch, which is accumulated in an animal's 30 and plant's body as a polysaccharide for storage, is one kind of glucan, it is a component which is always present in a body of a human, and is excellent in biocompatibility. Further, the glucan undergoes hydrolysis by -amylase in EG037PCT a body, and is converted into glucose or a maltooligosaccharide being a component which is always present in a body. For this reason, the glucan can be said to be the safest macromolecular material.
[0017] The 5 glucan has another advantage that design of its structure is relatively easy. Methods for controlling the molecular weight, degree of branching, cyclization and the like of the glucan are known. Completely linear glucans in which glucose residues are bound only with an -1,4-bond, 10 glucans which are branched at high frequency by some glucose residues bound with an -1,6-bond, and the like are available. In a branched glucan, every time an -1,6-bond is increased, one new non-reducing end is generated. The number of -1,6-bonds can be suitably adjusted according to desire 15 upon synthesis of a glucan molecule.
[0018] On the other hand, the greatest problem when the glucan is utilized as the modifying material for the medically effective ingredient is that it does not have a functional group which can bind to or interact with the medically 20 effective ingredient. It is possible to introduce a cationic or anionic functional group into a large number of hydroxyl groups present in a glucan by a chemical reaction. However, when such a procedure is used, the position of introduction of the functional group to the glucan is random and it is 25 difficult to obtain a modifying material of the same quality. Therefore, this procedure is not preferable for utilization in medicaments.
[0019] For this reason, it is sought to provide a modifying material suitable for utilizing in medicaments for a 30 medically effective ingredient, especially for a negatively-charged medically effective ingredient. MEANS FOR SOLVING THE PROBLEMS
[0020] In order to solve the aforementioned problems, the EG037PCT present inventors thought that specific introduction of an amino sugar (for example, glucosamine) into a non-reducing end of a high-molecular weight glucan chain is the extremely ideal method of modifying a glucan. If an amino sugar (for example, 5 glucosamine) can be selectively introduced into a non-reducing end of a high-molecular weight glucan, since the introduction position is not random, the same quality material can be produced reproductively, and the resulting product is suitable for utilization in medicaments. In 10 addition, there is no anxiety for toxicity by administering an amino sugar. The reason is that glucosamine is a monosaccharide having an amino group, sold as a supplement or a health food as a single component or as a mixture with chondroitin (chondroitin sulfate), and has low anxiety for 15 safety. Further, the amino group of an amino sugar (for example, glucosamine) is available for binding with a medically effective ingredient. Furthermore, an amino sugar (for example, glucosamine) becomes a sugar residue having a positive charge in an aqueous solution. For this 20 reason, by introducing an amino sugar residue into a glucan chain, it is possible to give a property to interact with a negatively-charged molecule (for example, a medically effective ingredient which is negatively charged in an aqueous solution) to a glucan chain. Example of 25 negatively-charged molecules includes a nucleic acid. A biodegradable carrier which binds to a molecule negatively charged in an aqueous solution and has no anxiety for staying in a body has not been known to date. For this reason, the glucan of the present invention can be said to be a useful 30 carrier in a bio DDS technique using a nucleic acid which has been paid attention in recent years.
[0021] The present inventors found that -glucan phosphorylase can utilize as a substrate an amino EG037PCT sugar-1-phosphate (for example, glucosamine-1-phosphate) which is not its original substrate, can transfer an amino sugar residue to a non-reducing end of a glucan receptor, and in spite of this, this enzyme can hardly catalyze the reverse reaction thereof, and completed the present 5 invention based on this finding. -glucan phosphorylase is an enzyme which, when acts on glucose-1-phosphate which is the original substrate, catalyzes both a reaction wherein a glucose residue is transferred to a glucan receptor (glucan 10 synthesizing reaction) and a reaction wherein the glucose on the non-reducing end of a glucan is phosphorolysed to generate glucose-1-phosphate (glucan degrading reaction). However, surprisingly, when this enzyme uses an amino sugar-1-phosphate (for example, glucosamine-1-phosphate) 15 as a substrate, this enzyme catalyzes the reaction wherein an amino sugar residue is transferred to a glucan receptor (glucan synthesizing reaction), but hardly catalyzes the reaction wherein an amino sugar residue on the non-reducing end of a glucan is phosphorolysed to generate an amino 20 sugar-1-phosphate (glucan degrading reaction). While glucan degrading reaction releases again the bound amino sugar residue, the present inventors found that in the method of the present invention, -glucan phosphorylase hardly catalyzes the glucan degrading reaction. That is, the 25 catalytic activity for the synthesizing reaction is much higher than the catalytic activity for the degradation reaction. Due to this characteristic, if a glucan has a plurality of non-reducing ends, -glucan phosphorylase can bind amino sugar residues (for example, glucosamine residues) 30 one by one to the plurality of non-reducing ends of the glucan. By utilizing this characteristic of this enzyme, the amino sugar-containing glucan of the present invention became producible for the first time. Especially, it could be EG037PCT obtained for the first time by utilizing this characteristic of this enzyme that a non-reducing end-modified glucan having high frequency of (for example, 50% or more) binding rate of amino sugar residues (for example, glucosamine residues) to the non-reducing ends, starting 5 with a glucan having a large number of (for example, 5 or more) non-reducing ends.
[0022] In the present specification, an amino sugar means that it is a sugar having an amino group. The sugar constructing the backbone monosaccharide of an amino sugar 10 can be a monosaccharide (for example, glucose) or an oligosaccharide. In the present specification, an oligosaccharide means a compound wherein 2 or more and 10 or less monosaccharides are linked. The degree of polymerization of an amino oligosaccharide bound to one 15 non-reducing end of the amino sugar-containing glucan of the present invention can be, for example, about 2 or more, about 3 or more, about 4 or more, about 5 or more or the like, and can be, for example, about 10 or less, about 9 or less, about 8 or less, about 7 or less, about 6 or less, 20 about 5 or less, about 4 or less, about 3 or less, about 2 or less or the like. In one embodiment, the amino oligosaccharide bound to one non-reducing end of the amino sugar-containing glucan of the present invention has 2 sugars (that is, a dimer). In the present specification, an amino 25 monosaccharide refers to an amino sugar wherein the sugar backbone is a monosaccharide. In the present specification, an amino oligosaccharide refers to an amino sugar wherein the sugar backbone is an oligosaccharide.
[0023] In addition, since a bond by an electrostatic 30 interaction does not bind molecules directly, it is thought that if a glucan is degraded from the conjugate to separate the medically effective ingredient, the medically effective ingredient retains the original stereostructure again. For EG037PCT this reason, the bond by an electrostatic interaction is thought as an ideal binding mode between a medically effective ingredient and a carrier. However, the bond by an electrostatic interaction is prone to be affected by the concentration of salts, and expected 5 ed to be unstable in a living body. Therefore, it is desirable to control strictly the position and number of amino sugars (for example, glucosamines) bound to a glucan molecule in order to control the strength of the bond with a nucleic acid and the form 10 of the associate.
[0024] Further, the present inventors found that a glucosamine-containing glucan wherein at least one glucosamine residue is bound to each of one or more (preferably two or more) non-reducing ends of a glucan has a function 15 to non-covalently bind to a nucleic acid to increase the apparent molecular weight of the nucleic acid.
[0025] Furthermore, the present inventors found that the strength of the bond with a nucleic acid and the form of the associate can be controlled by controlling the number 20 of amino monosaccharide residues such as glucosamine residues bound to a glucan molecule.
[0026] The present inventors found that a glucan wherein amino sugar residues are bound only to the ends of a plurality of glucan chains having appropriate degree of freedom can 25 be produced, and that a medically effective ingredient and a carrier can be bound via a stable electrostatic interaction, by development of a novel amino sugar-containing glucan.
[0027] In the amino sugar-containing glucan, a modified product thereof and a conjugate thereof of the present 30 invention, an amino sugar residue is bound only to a non-reducing end of the glucan. In preferred embodiments of the present invention, the amino sugar residue is glucosamine residue, galactosamine residue or mannosamine EG037PCT residue, or an oligomeric (for example, a dimeric) residue of sole or the combination thereof, and most preferably, glucosamine residue. In the glucosamine-containing glucan, a modified product thereof and a conjugate thereof of the present invention, a glucosamine residue 5 esidue is bound only to a non-reducing end of the glucan. In the present invention, transfer of an amino sugar (for example, glucosamine) residue is performed using -glucan phosphorylase (EC 2.4.1.1). For this reason, binding of an amino sugar (for example, 10 glucosamine) residue to a glucan is an -1,4-bond. That is, the carbon atom at 4-potision of a glucosyl residue at the end of glucan and the carbon atom at 1-position of an amino sugar (for example, glucosamine) residue are -bound through an oxygen atom. An enzyme which can transfer an amino sugar 15 (for example, glucosamine) to a glucan directly in a high yield has not been found other than this enzyme. Since the present amino sugar-containing glucan, a modified product thereof and a conjugate thereof have an amino sugar on a terminus, a glucan terminus comes to be positively charged 20 in an aqueous solution, and a physicochemical nature of the glucan is changed. The present amino sugar-containing glucan, a modified product thereof and a conjugate thereof are expected to be widely utilized in foods, cosmetics, medicaments and the like. 25 [0028] The introduction amount of amino sugar (for example, glucosamine) residues to a glucan can be controlled by the branching frequency of the glucan used and the frequency of introduction of amino sugar (for example, glucosamine) residues to a non-reducing end. When one wants to increase 30 an amount of introduction of an amino sugar (for example, glucosamine) residue into a glucan, it is possible to increase the introduction amount by using a glucan having a high branching frequency and increasing the frequency of EG037PCT introduction of amino sugars (for example, glucosamines) to the non-reducing end. When one wants to decrease an amount of introduction of an amino sugar (for example, glucosamine) residue into a glucan, it is possible to decrease the introduction amount by using a glucan having a low 5 branching frequency or decreasing the frequency of introduction of amino sugars (for example, glucosamines) to the non-reducing end. The lower limit of the introduction amount of amino sugar (for example, glucosamine) residues to a glucan is 10 the state wherein one amino sugar (for example, glucosamine) residue is introduced per glucan molecule, which can be attained by introducing an amino sugar (for example, glucosamine) residue to the non-reducing end of the glucan having no branching. Further, since the introduction 15 position is at an end, it is thought to exert no influence on degradability of a glucan by -amylase. In the case of a glucan which is highly branched, since non-reducing ends are distributed in an outermost layer of a glucan molecule, introduced amino sugar (for example, glucosamine) residues 20 are distributed in an outermost layer of a glucan molecule after introduction of an amino sugar (for example, glucosamine) residue, and this is ideal for interaction and binding with the medically effective ingredient. As described above, a glucan which has an amino sugar (for example, 25 glucosamine) residue selectively bound to a non-reducing end can be an excellent modifying material for the medically effective ingredient.
[0029] For example, the present invention provides the followings: 30 (Item 1) An amino sugar-containing glucan, wherein at least one amino monosaccharide residue is bound via an -1,4-bond to each of at least one non-reducing end of a glucan, but no amino EG037PCT sugar residue is present at the position other than the non-reducing end of the glucan, wherein the glucan is a branched -1,4-glucan or a linear -1,4-grucan, and the degree of polymerization of the glucan is about 10 or more and about 1 x 105 5 or less, and preferably about 15 or more and about 4 x 105 or less. (Item 2) The amino sugar-containing glucan according to item 1, wherein the glucan is a branched -1,4-glucan, the glucan 10 has a plurality of non-reducing ends, and at least one amino monosaccharide residue is bound via an -1,4-bond to each of at least one (preferably two ore more) non-reducing ends of the branched -1,4-glucan. That is, the amino sugar-containing glucan is an amino sugar-containing 15 branched glucan wherein the glucan has a plurality of non-reducing ends and at least one amino monosaccharide residue is bound via an -1,4-bond to each of at least one (preferably two or more) non-reducing ends of the branched -1,4-glucan, but no amino sugar residue is present at the 20 position other than the non-reducing end of the branched -1,4-glucan, wherein the degree of polymerization of the branched -1,4-glucan is about 10 or more and about 1 x 105 or less, and about 15 or more and about 4 x 105 or less. (Item 3) 25 The amino sugar-containing glucan according to item 2, wherein the branched -1,4-glucan is selected from the group consisting of a branched maltooligosaccharide, a starch, amylopectin, glycogen, dextrin, enzymatically synthesized branched glucan and highly branched cyclic glucan. 30 (Item 4) A hydroxyl group-modified product of the amino sugar-containing glucan according to any one of items 1 to 3, wherein the modification on the hydroxyl group is a EG037PCT modification on some or all of alcoholic hydroxyl groups of the glucan, and the modification on the hydroxyl group is independently selected from the group consisting of hydroxyalkylation, alkylation, acetylation, 5 carboxymethylation, sulfation and phosphorylation. (Item 5) A reducing end-modified product of the amino sugar-containing glucan according to any one of items 1 to 3 or a hydroxyl group-modified product thereof. 10 (Item 6) An amino group-modified product of the amino sugar-containing glucan according to any one of items 1 to 3, a hydroxyl group-modified product thereof or a reducing end-modified product thereof, wherein the modification on the amino group 15 is a modification on some or all of amino groups of the amino monosaccharide residues, the modification on the amino group is attained by a reaction of the amino group and an amino group-modifying reagent, and the amino group-modifying reagent has at least one carboxyl group and at least one 20 other functional group. (Item 7) A non-reducing end-modified product of the amino sugar-containing glucan according to any one of items 1 to 3, a hydroxyl group-modified product thereof, a reducing 25 end-modified product thereof or an amino group-modified product thereof, wherein a targeting molecule is bound to at least one of non-reducing ends to which the glucosamine residue of the glucan is not bound, or to the 4-position of the glucosamine residue, wherein the targeting molecule 30 is selected from the group consisting of mannose, galactose, glucuronic acid, N-acetylglucosamine, xylose, fucose, galactosamine, an antibody, an antibody fragment, a receptor, a receptor fragment and a receptor ligand. EG037PCT (Item 8) A method for producing an amino sugar-containing glucan, characterized by allowing an -glucan phosphorylase to act on an aqueous solution comprising a glucan and an amino 5 sugar-1-phosphate, wherein the glucan is a branched -1,4-glucan or a linear -1,4-glucan, and the degree of polymerization of the glucan is about 10 or more and about 1 x 105 or less, and preferably about 15 or more and about 4 x 105 or less. 10 (Item 9) The method according to item 8, wherein the -glucan phosphorylase has 95% or more sequence identity with the amino acid sequence of -glucan phosphorylase derived from Aquifex aeolicus VF5, and has activity of transferring an 15 amino sugar to a non-reducing end of a branched glucan to form an -1,4-bond. (Item 10) A medicament comprising the amino sugar-containing glucan according to any one of items 1 to 3, a hydroxyl group-modified 20 product thereof, a reducing end-modified product thereof, an amino group-modified product thereof, or a non-reducing end-modified product thereof, and a medically effective ingredient. (Item 11) 25 The medicament according to item 10, wherein the medically effective ingredient is selected from the group consisting of a low-molecular weight organic compound, a protein, a peptide, an antibody, an antibody fragment, a receptor, a receptor fragment, a DNA, an RNA, a siRNA, an miRNA and an 30 RNA aptamer. (Item 12) A composition for clinical diagnosis comprising the amino sugar-containing glucan according to any one of items 1 to EG037PCT 3, a hydroxyl group-modified product thereof, a reducing end-modified product thereof, an amino group-modified product thereof, or a non-reducing end-modified product thereof. 5 (Item 13) A nanoparticulate carrier for a DDS comprising the amino sugar-containing glucan according to any one of items 1 to 3, a hydroxyl group-modified product thereof, a reducing end-modified product thereof, an amino group-modified 10 product thereof, or a non-reducing end-modified product thereof. (Item 14) The carrier according to item 13, wherein the nanoparticulate carrier for a DDS is selected from the group consisting of 15 a liposome, a virus particle, a macromolecule micelle and a nanogel composed of macromolecule bearing hydrophobic groups. (Item 15) A complex formed with a nucleic acid molecule comprising 20 a gene which can be expressed in a cell and the amino sugar-containing branched glucan according to item 1. (Item 16) The complex according to item 15, wherein the nucleic acid molecule is selected from the group consisting of a DNA, 25 an RNA, a siRNA, an miRNA and an RNA aptamer. (Item 17) A complex formed with the complex carrier according to item 15 or 16, and a cationic polymer or a cationic lipid. (Item 18) 30 The complex according to item 17, wherein the cationic polymer comprises at least one cationic polymer selected from the group consisting of polyethyleneimine, polylysine, polyarginine, polyamidoamine dendrimer, poly(aminostyrene), EG037PCT chitosan, a cationic glucan and DEAE-dextran. (Item 19) A method for delivering a nucleic acid molecule into an isolated cell, comprising contacting the complex according 5 to any one of items 15 to 18 with the cell.
[0030] In one embodiment, the amino sugar is glucosamine, and in that case, the present invention is as follows: (Item 1A) A glucosamine-containing glucan, wherein at least one 10 glucosamine residue is bound via an -1,4-bond to each of at least one non-reducing end of a glucan, but no glucosamine residue is present at the position other than the non-reducing end of the glucan, wherein the glucan is a branched -1,4-glucan or a linear -1,4-grucan, and the degree of 15 polymerization of the glucan is about 10 or more and about 1 x 105 or less, and preferably about 15 or more and about 4 x 105 or less. That is, the glucosamine-containing glucan is a glucosamine-containing branched glucan wherein the glucan has a plurality of non-reducing ends and at least 20 one glucosamine residue is bound via an -1,4-bond to each of at least one (preferably two or more) non-reducing ends of the branched -1,4-glucan, but no glucosamine residue is present at the position other than the non-reducing ends of the glucan, wherein the degree of polymerization of the branched -1,4-glucan is about 10 or more and about 1 x 105 25 or less, and preferably about 15 or more and about 4 x 105 or less. (Item 2A) The glucosamine-containing glucan according to item 1A, 30 wherein the glucan is a branched -1,4-glucan, the glucan has a plurality of non-reducing ends, and at least one glucosamine residue is bound to each of at least one non-reducing end of the branched -1,4-glucan. EG037PCT (Item 3A) The glucosamine-containing glucan according to item 2A, wherein the branched -1,4-glucan is selected from the group consisting of a branched maltooligosaccharide, a starch, 5 amylopectin, glycogen, dextrin, enzymatically synthesized branched glucan and highly branched cyclic glucan. (Item 4A) A hydroxyl group-modified product of the glucosamine-containing glucan according to any one of items 10 1A to 3A, wherein the modification on the hydroxyl group is a modification on some or all of alcoholic hydroxyl groups of the glucan, and the modification on the hydroxyl group is independently selected from the group consisting of hydroxyalkylation, alkylation, acetylation, 15 carboxymethylation, sulfation and phosphorylation. (Item 5A) A reducing end-modified product of the glucosamine-containing glucan according to any one of items 1A to 3A or a hydroxyl group-modified product thereof. 20 (Item 6A) An amino group-modified product of the glucosamine-containing glucan according to any one of items 1A to 3A, a hydroxyl group-modified product thereof or a reducing end-modified product thereof, wherein the 25 modification on the amino group is a modification on some or all of amino groups of the glucosamine residues, the modification on the amino group is attained by a reaction of the amino group and an amino group-modifying reagent, and the amino group-modifying reagent has at least one 30 carboxyl group and at least one other functional group. (Item 7A) A non-reducing end-modified product of the glucosamine-containing glucan according to any one of items EG037PCT 1A to 3A, a hydroxyl group-modified product thereof, a reducing end-modified product thereof or an amino group-modified product thereof, wherein a targeting molecule is bound to at least one of non-reducing ends to which the glucosamine residue of the glucan is 5 not bound, wherein the targeting molecule is selected from the group consisting of mannose, galactose, glucuronic acid, N-acetylglucosamine, xylose, fucose, galactosamine, an antibody, an antibody fragment, a receptor, a receptor fragment and a receptor 10 ligand. (Item 8A) A method for producing a glucosamine-containing glucan, characterized by allowing an -glucan phosphorylase to act on an aqueous solution comprising a glucan and 15 glucosamine-1-phosphate, wherein the glucan is a branched -1,4-glucan or a linear -1,4-glucan, and the degree of polymerization of the glucan is about 10 or more and about 1 x 105 or less, and preferably about 15 or more and about 4 x 105 or less. 20 (Item 9A) The method according to item 8A, wherein the -glucan phosphorylase has 95% or more sequence identity with the amino acid sequence of -glucan phosphorylase derived from Aquifex aeolicus VF5, and has activity of transferring 25 glucosamine to a non-reducing end of a branched glucan to form an -1,4-bond. (Item 10A) A medicament comprising the glucosamine-containing glucan according to any one of items 1A to 3A, a hydroxyl 30 group-modified product thereof, a reducing end-modified product thereof, or an amino group-modified product thereof, and a medically effective ingredient. (Item 11A) EG037PCT The medicament according to item 10A, wherein the medically effective ingredient is selected from the group consisting of a low-molecular weight organic compound, a protein, a peptide, an antibody, an antibody fragment, a receptor, a receptor fragment, a DNA, an RNA, an miRNA and an RNA ap5 tamer. (Item 12A) A composition for clinical diagnosis comprising the glucosamine-containing glucan according to any one of items 1A to 3A, a hydroxyl group-modified product thereof, a 10 reducing end-modified product thereof, or an amino group-modified product thereof. (Item 13A) A nanoparticulate carrier for a DDS comprising the glucosamine-containing glucan according to any one of items 15 1A to 3A, a hydroxyl group-modified product thereof, a reducing end-modified product thereof, or an amino group-modified product thereof. (Item 14A) The carrier according to item 13A, wherein the 20 nanoparticulate carrier for a DDS is selected from the group consisting of a liposome, a virus particle, a macromolecule micelle and a nanogel composed of macromolecule bearing hydrophobic groups. (Item 15A) 25 A complex formed with a nucleic acid molecule comprising a gene which can be expressed in a cell and the glucosamine-containing branched glucan according to any one of items 1A to 3A. (Item 16A) 30 The complex according to item 15A, wherein the nucleic acid molecule is selected from the group consisting of a DNA, an RNA, a siRNA, an miRNA and an RNA aptamer. (Item 17A) EG037PCT A complex formed with the complex carrier according to item 15A or 16A, and a cationic polymer or a cationic lipid. (Item 18A) The complex according to item 17A, wherein the cationic 5 polymer comprises at least one cationic polymer selected from the group consisting of polyethyleneimine, polylysine, polyarginine, polyamidoamine dendrimer, poly(aminostyrene), chitosan, a cationic glucan and DEAE-dextran. (Item 19A) 10 A method for delivering a nucleic acid molecule into a cell, comprising contacting the complex according to any one of item 15A to 18A with the cell. EFFECTS OF THE INVENTION 15 [0031] In the amino sugar-containing glucan, a hydroxyl group-modified product thereof, a reducing end-modified product thereof, an amino group-modified product thereof and a conjugate thereof of the present invention, an amino sugar residue is bound only to a non-reducing end of the 20 glucan. Since the present amino sugar-containing glucan, a hydroxyl group-modified product thereof, a reducing end-modified product thereof, an amino group-modified product thereof and a conjugate thereof have amino sugar on a terminus, a glucan terminus comes to be positively charged 25 in an aqueous solution, and a physicochemical nature of the glucan is changed. The present amino sugar-containing glucan, a hydroxyl group-modified product thereof, a reducing end-modified product thereof, an amino group-modified product thereof and a conjugate thereof are expected to be 30 widely utilized in foods, cosmetics, medicaments and the like. These glucans have the characteristics that, when used as a carrier for a medically effective ingredient, due to the bond by an electrostatic interaction, these glucans do EG037PCT not change in quality largely the chemical structure of the medically effective ingredient, and can bind a plurality of amino sugars to the non-reducing end per carrier molecule, therefore, these glucans can retain the medically effective 5 ingredient stably.
[0032] Since the amino sugar-containing glucan, a hydroxyl group-modified product thereof, a reducing end-modified product thereof, and an amino group-modified product thereof of the present invention can increase a half-life in blood 10 than that of an unmodified glucan, and ultimately completely degraded in a living body and excreted from kidney, they have extremely high safety. For this reason, they are useful as a modifying material for a medically effective ingredient, a clinical diagnostic agent, a contrast agent and a 15 nanoparticulate carrier for DDS. In the amino sugar-containing glucan, a hydroxyl group-modified product thereof, a reducing end-modified product thereof, and an amino group-modified product thereof of the present invention, since their structure can be controlled by an enzymatic 20 reaction, they are also excellent in quality stability.
[0033] In the amino sugar-containing glucan and a modified product thereof of the present invention, since an amino sugar residue is bound only to a non-reducing end of the glucan, a site which interacts with other molecules and a 25 site which suppresses degradation can be structurally separated. Further, the amino sugar-containing glucan and a modified product thereof of the present invention have been appropriately suppressed the degradation compared to naturally-occurring glucan, the interaction with other 30 molecules is not too strong, and can appropriately release other molecule as the glucan moiety is degraded, therefore, they can give an appropriate degradability to other molecule by association with the other molecule. In addition, the EG037PCT amino sugar-containing glucan and a modified product thereof and a conjugate thereof of the present invention are degraded with an enzyme in a body, and therefore it does not cause the problem of residual property due to staying in a body 5 for an excessively long term.
[0034] When the amino sugar-containing glucan and a modified product thereof of the present invention are associated with a negatively-charged substance such as a nucleic acid molecule, it is possible to control the molecular weight 10 of the associate. Since in view of safety, stability of the result, and reproducibility, it is preferable that the molecular weight of an administered product in DDS can be controlled, the amino sugar-containing glucan and a modified product thereof of the present invention can effectively 15 be utilized as an excellent carrier for DDS. BRIEF DESCRIPTION OF THE DRAWINGS
[0035] [Fig. 1] Fig. 1 is a schematic view of a reaction of 20 transferring a glucosamine residue to a non-reducing end of a branched glucan. The structure of the part shown with an asterisk is shown in the square frame. [Fig. 2] Fig. 2 is results of analysis of an enzymatically treated product of a branched glucan obtained in Production 25 Example 2, and an enzymatically treated product of the product obtained by allowing Aquifex aeolicus VF5-derived -glucan phosphorylase in Production Example 1 to act on glucosamine-1-phosphate and the branched glucan of Production Example 2 (the product obtained in Example 1), 30 with a HPAEC-PAD apparatus manufactured by DIONEX. The horizontal axis represents the elusion time (minutes). A shows the result obtained by analyzing the degradation product after degrading the branched portions of the branched EG037PCT glucan with the sufficient amount (that is, excess amount) of isoamylase to cleave all the branches. Regarding numbers above the peaks in Fig. 2A, 6 indicates maltohexaose, and 7 indicates maltoheptaose. The peaks shown with black solid 5 circles thereabove indicate, from left to right, maltooligosaccharides having the degree of polymerization of glucose of from 8 to 14. Fig. 2B shows the result obtained by analyzing the degradation product obtained after degrading the branched glucan with an excess amount of isoamylase, 10 and then further degrading it with an excess amount of microorganism-derived -glucosidase. Since -glucosidase is an enzyme which degrades glucan in glucose units starting from the non-reducing end, the branched glucan was completely degraded and the peak of glucose (shown by "Glucose" in Fig. 15 2B) was detected. Fig. 2C shows the result obtained by analyzing the degradation product obtained after degrading the glucosamine-containing branched glucan obtained in the present Example 1 with an excess amount of isoamylase. While the peaks shown with black solid circles in Fig. 2C correspond 20 to the peaks detected at the same elusion time as the peaks shown with black solid circles at the corresponding positions in Fig. 2A, the peaks shown with "x" having different intervals therefrom were detected. Fig. 2D shows the result obtained by analyzing the degradation product obtained after degrading 25 the glucosamine-containing branched glucan obtained in the present Example 1 with isoamylase and further degrading with an excess amount of microorganism-derived -glucosidase. The group of peaks shown with black solid circles disappeared due to the degradation, and as a result, the peak of glucose 30 (shown by "Glucose" in Fig. 2D) appeared, however, the peaks shown with "x" did not disappeare. That is, the partially degraded product indicated by the peaks shown with "x" exhibited resistance to degradation with -glucosidase. EG037PCT Fig. 2E shows the result obtained by analyzing the degradation product obtained after degrading the glucosamine-containing branched glucan obtained in the present Example 1 with an excess amount of isoamylase, and further degrading with an excess amount of microorganism-derived 5 -glucosidase and an excess amount of -amylase simultaneously. As a result, in addition to the peak of glucose, the peaks shown with asterisks were detected. The peaks shown with asterisks indicate glucosamine-containing oligosaccharide 10 (trisaccharide), which is the smallest unit which cannot be degraded with -amylase and -glucosidase, and therefore, it can be understood that a glucan which has a glucosamine residue bound to the non-reducing end was obtained. [Fig. 3] Fig. 3 is a figure showing formation of a complex 15 of the glucosamine-containing glucan of Example 1 and a DNA. Relative to 0.5 g of a lambda DNA-Hind III fragment, ion-exchanged water for Sample 1, 0.1 mg of branched glucan for Sample 2, 0.5 mg of branched glucan for Sample 3, 0.1 mg of glucosamine-containing branched glucan for Sample 4, 20 0.5 mg of glucosamine-containing branched glucan for Sample 5, the same molar concentration of glucosamine as that of glucosamine unit contained in Sample 4 for Sample 6, the same molar concentration of glucosamine as that of glucosamine unit contained in Sample 5 for Sample 7 were 25 added respectively, and they were allowed to stand at room temperature in 10 l for 5 minutes, then 1% agarose gel electrophoresis were performed. While bands (a) were detected for Samples 1 to 3, DNA did not migrate through agarose gel when glucosamine-containing branched glucan were 30 added (b). Therefore, it could be understood that the cationized glucosamine-containing branched glucan can form a complex with a DNA. In addition, in Samples 6 and 7 to which glucosamine were added, the mobility were not changed EG037PCT as compared with the case where the glucosamine was not added, and it could be understood that glucosamine has no effect to increase the molecular weight of a DNA. [Fig. 4] Fig. 4 is a figure showing the binding force between oligo(5 dT)-cellulose and the glucosamine-containing branched glucans of Example 3 (BN5 and BN6) or the glucosamine-containing branched glucan of Example 4 (PN6). Oligo(dT)-cellulose was suspended in NaCl solutions of each concentration (0.1 M, 0.2 M, 0.3 M, 0.5 M, 1 M, or 2 M), 10 and the glucosamine-containing branched glucan obtained in Example 3 or Example 4 was added and allowed to stand at room temperature for 30 minutes, then centrifuged, and measured the amount of glucosamine-containing branched glucans which were not bound with oligo(dT)-cellulose 15 contained in the supernatant fraction, thereby calculated the percentage (%) of the amount of bound cationized glucan (total sugar amount) relative to the amount of added glucosamine-containing glucan (total sugar amount). The obtained results are shown as a graph. It can be understood 20 that PN6 separates from a nucleic acid at 1 M or more of NaCl. It can be understood that BN6 separates from a nucleic acid at 0.5 M or more of NaCl. It can be understood that BN5 separates from a nucleic acid at 0.2 or more. There was a tendency that the more number of glucosamine residues 25 contained in one molecule of glucosamine-containing branched glucan, the higher the NaCl concentration at which these residues separates. Therefore, the binding force with a nucleic acid could be controlled by controlling the frequency at which glucosamine was bound to a branched glucan. In the 30 case where polylysine was used, polylysine bound with a nucleic acid strongly, and did not separate from the nucleic acid even in 2 M of NaCl. [Fig. 5] Fig. 5 is a figure showing the transfection efficiency EG037PCT of macrophage cell line in the case where the glucosamine-containing branched glucan of Example 4 (PN6) was used. The glucosamine-containing branched glucan was incubated with a plasmid containing LUC gene encoding 5 firefly-derived luciferase for 24 hours, and thereafter, luciferase activity was measured. As shown in Fig. 5, it can be understood that PN6 shows a transfection function, and especially, the highest transfection efficiency was shown when N/P ratio was 200. While polyethyleneimine showed high 10 transfection efficiencies at N/P ratios of 10 and 50, the efficiency remarkably lowered when N/P ratio was 200. Polylysine showed the highest transfection efficiency when N/P ratio was 2, and the efficiency remarkably lowered when N/P ratio was higher than 10. 15 [Fig. 6] Fig. 6 is a figure evaluating the cytotoxicity in transfection of macrophage cell line when the glucosamine-containing branched glucan of Example 4 (PN6) was used. The protein concentration in the supernatant of the cell lysate obtained in Example 11 was measured and used 20 as a measure of toxicity. As shown in Fig. 6, it is shown that PN6 has low toxicity to a cell. When polyethyleneimine and polylysine were used, remarkable toxicity was observed at N/P ratios of 50 and 200. 25 MODE FOR CARRYING THE INVENTION
[0036] The present invention will be explained in detail below.
[0037] Throughout the present specification, it should be understood that expression in a singular form includes a 30 concept of a plural form thereof, unless otherwise indicated. In addition, it should be understood that a term used in the present specification is used in a sense which is usually used in the art, unless otherwise indicated. EG037PCT
[0038] (General Techniques) The molecular biological procedures, biochemical procedures, and microbiological procedures used in the present specification are well known and routine in the art, and described in, for example, Sambrook, J. et al., 5 ., (1989). Molecular Cloning: A Laboratory Manual, Cold Spring Harbor and its 3rd Ed. (2001); Ausubel, F.M. (1987). Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience; Ausubel, F.M. (1989). Short Protocols 10 in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Greene Pub. Associates and Wiley-Interscience; Innis, M.A. (1990). PCR Protocols: A Guide to Methods and Applications, Academic Press; Ausubel, F.M. (1992). Short Protocols in Molecular Biology: A 15 Compendium of Methods from Current Protocols in Molecular Biology, Greene Pub. Associates; Ausubel, F.M. (1995). Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Greene Pub. Associates; Innis, M.A. et al., (1995). PCR Strategies, 20 Academic Press; Ausubel, F.M. (1999). Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology, Wiley, and annual updates; Sninsky, J.J. et al., (1999). PCR Applications: Protocols for Functional Genomics, Academic Press, Bessatsu 25 Jikken-igaku "Idenshidounyu & Hatsugen kaiseki jikkenhou" (a separate volume of Experimental Medicine "Experimental methods for gene introduction and expression analysis"), Yodosha Co., Ltd., 1997, and the like, the related portions thereof (which can be the whole) are incorporated herein 30 by reference.
[0039] DNA synthetic techniques and nucleic acid chemistries for producing an artificially-synthesized gene are described in, for example, Gait, M.J. (1985). EG037PCT Oligonucleotide Synthesis: A Practical Approach, IRL Press; Gait, M.J. (1990). Oligonucleotide Synthesis: A Practical Approach, IRL Press; Eckstein, F. (1991). Oligonucleotides and Analogues: A Practical Approac, IRL Press; Adams, R.L. et al., (1992). The Biochemistry of the Nucleic Acids, Ch5 apman & Hall; Shabarova, Z. et al., (1994). Advanced Organic Chemistry of Nucleic Acids, Weinheim; Blackburn, G.M. et al., (1996). Nucleic Acids in Chemistry and Biology, Oxford University Press; Hermanson, G.T. (I996). Bioconjugate 10 Techniques, Academic Press, and the like, the related portions thereof are incorporated herein by reference.
[0040] When a gene is referred to in the present specification, a "vector" or a "recombinant vector" refers to a vector which can transfer an objective polynucleotide 15 sequence into an objective cell. Examples of such vectors include a vector which can autonomously replicate in a host cell, such as a prokaryotic cell, a yeast, an animal cell, a plant cell, an insect cell, an animal individual and a plant individual, or can be incorporated into a chromosome, 20 and has a promoter at a position suitable for transcribing the polynucleotide of the present invention. Among the vectors, those vectors which are suitable for cloning are referred to as "cloning vector". Such a cloning vector usually comprises a multiple-cloning site containing a 25 plurality of restriction enzyme sites. Such a restriction enzyme site and a multiple-cloning site are well known in the art, and those skilled in the art can select as appropriate and use them in accordance with the purpose. Such techniques are described in the documents described in the present 30 specification (for example, Sambrook, et al., supra). Preferred vectors include, but are not limited to, a plasmid, a phage, a cosmid, an episome, a viral particle or a virus, and an integratable DNA fragment (that is, a fragment which EG037PCT can be integrated into a host genome by homologous recombination).
[0041] One type of vectors is a "plasmid", which refers to a circular duplex DNA loop to which an additional DNA segment can be linked. Another 5 type of vector is a viral vector, wherein an additional DNA segment can be linked into a viral genome. Specific vectors (for example, bacterial vector having a bacterial origin of replication and an episome mammalian vector) can autonomously replicate in a host cell 10 to which these vectors are introduced. Other vectors (for example, non-episome mammalian vector) are integrated to a genome of a host cell upon introduction to the host cell, and thereby, replicated together with the host genome. In addition, specific vectors can direct expression of a gene 15 to which these vectors are operably linked. Such vectors are referred to as "expression vectors" in the present specification.
[0042] Therefore, in the present specification, an "expression vector" or an "expression plasmid" refers to 20 a nucleic acid sequence wherein various regulation elements, in addition to a structural gene and a promoter regulating its expression, are connected in a cell of a host in an operable condition. An expression vector is, preferably, a vehicle which is operably linked to an objective structural gene 25 such that the objective structural gene is transcripted and translated, and if necessary, contains factors necessary for replication in the host cell and selection of a recombinant. Regulation elements can include, preferably, a terminator, a selectable marker such as a drug resistant gene, and an 30 enhancer. It is well-known to those skilled in the art that the type of an expression vector of an organism (e.g. mammal), and the kind of regulation element used can vary depending on a host cell. When secretion production of an expressed EG037PCT product (-glucan phosphorylase or a medically effective ingredient) is intended, a polynucleotide encoding a secretion signal peptide is linked upstream of a DNA coding for the objective protein in the correct reading frame. [5 0043] Preferred expression vectors include pTRC99A (manufactured by Pharmacia) that is also expressible in Escherichia coli, and the like. In order to operably link an -glucan phosphorylase gene to factors necessary for transcription and translation in the aforementioned 10 expression vector, an objective -glucan phosphorylase gene should be processed in some cases. Examples include the case where the distance between a promoter and a coding region is too long, and reduction in a transcription efficiency is predicted, the case where the distance between a ribosome 15 binding site and a translation initiation codon is not suitable, and the like. The process means include digestion with a restriction enzyme, digestion with an exonuclease such as Bal31 and ExoIII, or introduction of site-directed mutagenesis using a single-stranded DNA such as M13 or PCR. 20 [0044] As "recombinant vectors" for a prokaryotic cell which can be used in the present application, pcDNA3(+), pBluescript-SK(+/-), pGEM-T, pEF-BOS, pEGFP, pHAT, pUC18, pFT-DESTTM 42GATEWAY, pENTRTM/D-TOPO (Invitrogen), and the like are exemplified. A prokaryotic cell can be used in 25 amplification, modification and the like of a gene.
[0045] "Recombinant vectors" for an eukaryote cell which can be used in the present application include, but are not limited to, pECFP (Clontech), pAcGFP (Clontech), pEYFP (Clontech), pDsRED (Clontech), pTRE (Clontech), pCMV 30 (Clontech), pcDNA (Invitrogen), pTarget (Promega), and the like.
[0046] In the present specification, a "mammalian expression vector" refers to a nucleic acid sequence wherein EG037PCT various regulation elements such as a promoter regulating expression of the gene of the present invention are operably linked in a host cell. The term "regulation sequence" used in the specification of the present application refers to a DNA sequence having a functional promoter 5 romoter and any related transcription elements (for example, an enhancer, a CCAAT box, a TATA box, an SPI site, and the like). The term "operably linked" used in the specification of the present application refers that a polynucleotide related to a gene and various 10 regulation elements, such as a promoter and an enhancer, which regulate expression of the gene are connected in a host cell in an operable condition such that the gene can be expressed. A mammalian expression vector can preferably include a mammalian gene, a promoter, a terminator, a drug 15 resistant gene and an enhancer. It is well-known to those skilled in the art that the type of expression vector and the kind of regulation element used can vary depending on a host cell.
[0047] Mammalian expression vectors as described above can 20 be made using gene recombination techniques well-known to those skilled in the art. For construction of a mammalian expression vector, for example, a pECFP-type vector, a pcDNA-type vector or the like are preferably used, but not limited to them. 25 [0048] In the present specification, a "terminator" is a sequence which is situated downstream of a protein coding region of a gene, and is involved in termination of transcription upon transcription of a DNA into an mRNA, and in the addition of a poly A sequence. It is known that a 30 terminator contributes to the stability of an mRNA and influences the expression level of a gene.
[0049] In the present specification, a "promoter" refers to a region on a DNA which determines a transcription EG037PCT initiation site of a gene, and directly regulates the transcription frequency, and is a base sequence to which a RNA polymerase binds, thereby, initiating transcription. A putative promoter region varies with every structural gene, and is usually upstream 5 of a structural gene without limitation, and may be downstream of a structural gene. While a promoter may be inducible, constitutive, site-directed, or stage-specific, a constitutive promoter or an inducible promoter is preferable. Any promoter is 10 possible as long as which can be expressed in a host cell such as a mammalian cell, Escherichia coli, or a yeast.
[0050] In the present specification, expression of a promoter is "constitutive" means the nature by which the promoter is expressed at an almost fixed amount in all the 15 tissues in an organism at whatever stage of growth/proliferation of the organism. Specifically, in the definition of the present invention, when analyzed with Northern blot, if almost the same degree of expression amount is observed in either of the same or corresponding sites, 20 for example, at any time point (for example, at two or more points (for example, on day 5 and day 15)), the expression is said to be constitutive. It is believed that a constitutive promoter plays a role in maintenance of homeostasis of an organism in a normal growing environment. 25 "Responsive" expression of the promoter of the present invention means the nature by which the expression amount is changed when at least one factor is given to an organism. Especially, the nature by which expression amount is increased is referred to be "inducible" by a factor, and 30 the nature by which expression amount is decreased is referred to be "decreasing" by a factor. Since "decreasing" expression has a premise that expression is observed under a normal condition, it is an idea overlapping with EG037PCT "constitutive" expression. These natures can be determined by extracting an RNA from any portion of an organism and analyzing expression amount by Northern blot analysis, or quantifying the expressed protein by western blot. A 5 mammalian cell or a mammal (including a specific tissue or the like) transformed with a vector integrated a promoter inducible by a factor together with a nucleic acid encoding the site-directed recombination inducing factor of the present invention can perform a site-directed recombination 10 of a site-directed recombination sequence under a certain condition by using a stimulation factor having an inducible activity to the promoter.
[0051] The polynucleotide of the present invention can be linked intact or with modification into an appropriate 15 expression vector using a method well-known to those skilled in the art, and introduced to a host cell by a known gene recombination technique. The introduced gene exists integrated to a DNA in the host cell. It is noted that a DNA in a host cell includes not only a DNA included in a 20 chromosome but also a DNA included in various organelle (for example, a mitochondrion and the like) contained in a host cell.
[0052] When Escherichia coli is used as a host cell, promoters derived from Escherichia coli, phage and the like, 25 such as trp promoter (Ptrp), lac promoter (Plac), PL promoter, PR promoter, and PSE promoter, SPO1 promoter, SPO2 promoter, penP promoter, and the like can be included. In addition, an artificially designed and modulated promoters or the like such as a promoter consisting of two serially aligned 30 Ptrps(Ptrp x2), tac promoter, lacT7 promoter, let I promoter can also be used.
[0053] In the present specification, an "origin of replication" refers to a specific region on a chromosome EG037PCT from which DNA replication starts. An origin of replication can either be provided by constructing the vector so as to include an endogenous origin, or by a chromosomal replication mechanism of a host cell. The latter may be sufficient when the vector is integrated to a host 5 cell chromosome. Alternatively, those skilled in the art can transform a mammalian cell by co-transforming with a selectable marker and the DNA of the present invention, rather than by using a vector including a viral origin of replication. Examples 10 of suitable selectable markers are dihydrofolate reductase (DHFR) or thymidine kinase (see U.S. Patent No. 4,399,216).
[0054] In the present specification, "operably linked" refers to that expression (operation) of a desired sequence is placed under the control of a transcription and translation 15 regulating sequence (e.g. promoter, enhancer and the like) or a translation regulating sequence. In order that a promoter is operably linked to a gene, usually, a promoter is disposed immediately upstream of the gene, but it is not necessary that the promoter is disposed adjacent to the gene. 20 [0055] In the present specification, the technique of introducing a nucleic acid molecule into a cell may be any technique. Examples of such techniques include, for example, transformation, transduction, and transfection. Such techniques of introducing a nucleic acid molecule are 25 well-known in the art, and are conventional, and are described, for example, in Ausubel F.A. et al., ed. (1988), Current Protocols in Molecular Biology, Wiley, New York, NY; Sambrook J et al., (1987) Molecular Cloning: A Laboratory Manual, 2nd Ed. and 3rd Ed., Cold Spring Harbor Laboratory Press, 30 Cold Spring Harbor, NY; Bessatsu Jikken-igaku "Idenshidounyu & Hatsugen kaiseki jikkenhou" (a separate volume of Experimental Medicine "Experimental methods for gene introduction and expression analysis"), Yodosha Co., Ltd., EG037PCT 1997 and the like. The introduction of a gene can be confirmed using the methods described in the present specification such as Northern blot analysis and Western blot analysis, or other well-known and conventional techniques. 5 [0056] Further, as a method for introducing a vector, any method as described above for introducing a DNA to a cell can be used, the method include, for example, transfection, transduction, transformation and the like (for example, calcium phosphate method, liposome method, DEAE-dextran 10 method, electroporation method, method using a particle gun (a gene gun) and the like).
[0057] In the present specification, a "transformant" refers to a whole or a part of a living body such as a cell produced by transformation. Transformants are exemplified 15 by a prokaryotic cell, a yeast, an animal cell, a plant cell, an insect cell, and the like. A transformant can also be referred to as a transformated cell, a transformated tissue, or a transformated host, depending on the subject. The cell used in the present invention can be a transformant. 20 [0058] When a prokaryotic cell is used in gene manipulation or the like in the present invention, prokaryotic cells are exemplified by the prokaryotic cells belonging to a genus Escherichia, Serratia, Bacillus, Brevibacterium, Corynebacterium, Microbacterium, Pseudomonas, or the like, 25 for example, Escherichia coli XL1-Blue, Escherichia coli XL2-Blue, and Escherichia coli DH1.
[0059] As used in the present specification, as a method for introducing a recombinant vector, any methods which introduce a DNA can be used, the methods include, for example, 30 calcium chloride method, electroporation method [Methods. Enzymol., 194, 182 (1990)], lipofection method, spheroplast method [Proc. Natl. Acad. Sci. USA, 84, 1929 (1978)], lithium acetate method, and the like. EG037PCT
[0060] In the present specification, "detection" or "quantification" of gene expression (for example, mRNA expression, and polypeptide expression) can be achieved using a suitable method including, for example, measurement of mRNA and immunological measuring method. Mol5 ecular biological measuring methods are exemplified by, for example, Northern blot method, dot blot method, PCR method and the like. Immunological measuring methods are exemplified, for example, ELISA method using a microtiter plate, RIA method, 10 immunofluorescence method, western blot method, immunohistostaining, and the like, as the method. Further, quantifying methods are exemplified by ELISA method, RIA method or the like. It can be done by a gene analyzing method using an array (for example, a DNA array, and a protein array). 15 A DNA array is widely reviewed in (Shujunsha Ed., Saibo Kogaku Bessatsu, "DNA Microarray to Saishin PCR Hou"). A protein array is detailed in Nat Genet. 2002 Dec; 32 Suppl: 526-32. Methods for analyzing gene expression include, but are not limited to, RT-PCR, RACE method, SSCP method, 20 immunoprecipitation method, two-hybrid system, in vitro translation and the like, in addition to the above. Such additional analysis methods are described in, for example, Genomu kaiseki jikkenhou, Nakamura Yusuke lab manual (Understand the Basics of Genomics Experiments - Yusuke 25 Nakamura Laboratory Manual), Editor Yusuke Namamura, Yodosha Co., Ltd. (2002) and the like, the whole description of which is incorporated herein by reference.
[0061] (1. Materials) (1.1) Glucans and modified products of glucan 30 "Glucan", when used in the present specification, is a polysaccharide having D-glucose as a constituent unit. In the present invention, it is preferable to use, as the glucan, an -D-glucan. The bonds which link glucose residues in an EG037PCT -D-glucan predominantly consist of an -1,4-glucosidic bond, and can contain an -1,6-glucosidic bond. An -D-glucan containing a -1,6-glucosidic bond has a branched structure. A glucan having at least one -1,6-glucosidic bond in the molecule is referred 5 red to as a branched glucan, and a glucan having no -1,6-glucosidic bond in the molecule is referred to as a linear glucan. In the present specification, unless otherwise indicated, it is preferable that the weight average molecular weight of the "glucan" is about 1 x 103 or more. 10 Preferable glucans used in the present invention are a linear glucan and a branched glucan, more preferably a linear -1,4-glucan and an -1,4-glucan which is branched with an -1,6-bond (also referred to as a branched -1,4 glucan). It is preferable that the glucan used in the present invention 15 does not contain an -1,3-bond.
[0062] The linear -D-1,4-glucan refers to a polysaccharide in which two or more saccharide units of D-glucose units are bound only with an -1,4-glucosidic bond(s). In the present specification, unless otherwise indicated, the 20 linear -D-1,4-glucan is referred to as a linear glucan or a linear -1,4-glucan. The linear glucan has one non-reducing end. Examples of the linear glucan suitably utilized in the present invention include amylose.
[0063] In the present specification, the term "amylose" 25 refers to a linear molecule constructed of glucose units connected via -1,4-bonds. An amylose is contained in natural starch. Amylose may be a natural amylose extracted from a natural starch, or may be an amylose synthesized by an enzymatic reaction (also referred to as "enzymatically 30 synthesized amylose" in the present specification). Natural amylose may contain a branched part in some cases, but enzymatically synthesized amylose does not contain a branch. Further, natural amyloses have a large EG037PCT polydispersity and vary in the molecular weight, but an enzymatically synthesized amylose (particularly, an enzymatically synthesized amylose synthesized by the SP-GP method described in International Publication WO 02/097107 pamphlet) has a small 5 mall polydispersity and has an extremely uniform molecular weight. For this reason, in the present invention, it is preferable to use an enzymatically synthesized amylose. The degree of polymerization of the amylose used in the present invention is preferably about 10 10 or more, more preferably about 50 or more, still more preferably about 100 or more, and most preferably about 180 or more. The degree of polymerization of the amylose used in the present invention is preferably about 1 x 105 or less, more preferably about 1 x 104 or less, still more preferably about 1 x 103 15 or less and most preferably about 500 or less.
[0064] In the present specification, the term "branched -D-glucan" refers to a glucan in which a linear glucan, in which D-glucose units are connected with an -1,4-glucosidic bond(s), is branched with a bond other than 20 an -1,4-glucosidic bond. In the present specification, unless otherwise indicated, the branched -D-glucan is referred to as a branched glucan. A branching bond is either an -1,6-glucosidic bond, an -1,3-glucosidic bond, or an -1,2-glucosidic bond, and most preferably is an 25 -1,6-glucosidic bond. It is preferable that a branched -D-glucan used in the present invention does not contain an -1,3-glucosidic bond and an -1,2-glucosidic bond. The branched glucan usually has the same number of non-reducing ends as the number of branching bonds. When the branched 30 glucan is treated with an enzyme which selectively breaks only an -1,6-glucosidic bond (for example, isoamylase, pullulanase, or the like), the branched glucan can be degraded into a mixture of linear -1,4-glucans. These are referred EG037PCT to as a unit chain of the branched glucan, and the degree of polymerization thereof is referred to as a unit chain length.
[0065] Examples of the branched glucan suitably utilized 5 in the present invention include starches, amylopectin, glycogen, dextrin, enzymatically synthesized branched glucan and highly branched cyclic glucan.
[0066] In the present specification, the term "starch" is a mixture of amylose and amylopectin. As a starch, any starch 10 can be used as long as it is commonly commercially available. The ratio of the amylose and amylopectin contained in a starch is different depending on the kind of plant producing the starch. Almost all starches possessed by glutinous rice, glutinous corn and the like are an amylopectin. On the other 15 hand, a starch consisting only of amyloses, containing no amylopectin, can not be obtained from a common plant. Starch is classified into natural starch, a degraded starch and modified starch.
[0067] Natural starch is classified into tuber starch and 20 cereal starch depending on the raw material. Examples of tuber starches include potato starch, tapioca starch, sweet potato starch, kudzu starch, bracken starch and the like. Examples of cereal starches include corn starch, wheat starch, rice starch and the like. Examples of natural starches are 25 high amylose starches (for example, high amylose corn starch) or waxy starches. The starch can be a soluble starch. A soluble starch refers to a water-soluble starch obtained by subjecting a variety of treatment on natural starch. The starch may be selected from the group consisting of soluble 30 starch, waxy starch and high amylose starch. The starch may be a modified starch.
[0068] The degree of polymerization of the starch used in the present invention is preferably about 1 x 103 or more, EG037PCT more preferably about 5 x 103 or more, still more preferably about 1 x 104 or more, and most preferably about 2 x 104 or more. The degree of polymerization of the starch used in the present invention is preferably about 1 x 107 or less, more preferably about 3 x 106 or less, 5 s, still more preferably about 1 x 106 or less and most preferably about 3 x 105 or less.
[0069] An amylopectin is a branched molecule in which a glucose unit(s) is bound via an -1,6 bond to glucose units 10 which are bound via an -1,4 bond(s). An amylopectin is contained in natural starch. As an amylopectin, for example, waxy corn starch, which consists of 100% amylopectin, can be used. The degree of polymerization of the amylopectin used in the present invention is preferably about 1 x 103 or more, more preferably about 5 x 103 15 or more, still more preferably about 1 x 104 or more, and most preferably about 2 x 104 or more. The degree of polymerization of the amylopectin used in the present invention is preferably about 1 x 107 or less, more preferably about 3 x 106 or less, still more preferably about 1 x 106 20 or less and most preferably about 1 x 105 or less.
[0070] A glycogen is one kind of glucan constructed of glucose, and is a glucan having a high frequency of branching. A glycogen is widely distributed as a storage polysaccharide 25 for animals in almost all cells in the granule state. In a plant, glycogen is present, for example, in the seed of sweet corn species of corn. In a glycogen, typically, sugar chains consisting of glucoses bound via an -1,4-bond(s) which have an average degree of polymerization of 12 to 18 30 are bound by an -1,6-bond(s) at a ratio of around one chain every about 3 units of glucose, to a sugar chain consisting of glucoses bound via an -1,4-bond(s). In addition, similarly, a sugar chain consisting of glucoses bound by EG037PCT an -1,4-bond(s) is bound by an -1,6-bond to a branch chain bound by an -1,6-bond(s). For this reason, glycogen forms a network structure. It is also possible to enzymatically synthesize a glycogen. The degree of polymerization of the 5 glycogen used in the present invention is preferably about 500 or more, more preferably about 1 x 103 or more, still more preferably about 2 x 103 or more, and most preferably about 3 x 103 or more. The degree of polymerization of the glycogen used in the present invention is preferably about 1 x 107 or less, more preferably about 3 x 106 10 or less, still more preferably about 1 x 106 or less and most preferably about 3 x 105 or less.
[0071] Dextrin is one kind of glucan constructed of glucose, and is a glucan having a medium complexity between those 15 of starch and those of maltose. Dextrin is obtained by partially degrading starch by an acid, an alkyl or an enzyme. The degree of polymerization of the dextrin used in the present invention is preferably about 10 or more, more preferably about 20 or more, still more preferably about 30 or more, 20 and most preferably about 50 or more. The degree of polymerization of the dextrin used in the present invention is preferably about 1 x 104 or less, more preferably about 9 x 103 or less, still more preferably about 7 x 103 or less and most preferably about 5 x 103 or less. 25 [0072] The enzymatically synthesized branched glucan refers to a branched glucan synthesized using an enzyme. By adding a branching enzyme to the reaction solution upon synthesis of amylose by the SP-GP method, the product can be branched. The extent of branching can be regulated by 30 the added amount of the branching enzyme. Since the enzymatically synthesized branched glucan has a uniform structure as compared with a natural branched glucan, it is very advantageous when used as a pharmaceutical material. EG037PCT For example, the degree of polymerization of the enzymatically synthesized branched glucan used in the present invention is preferably about 10 or more, more preferably about 20 or more, still more preferably about 30 or more, and most preferably about 500 or more. The 5 degree of polymerization of the enzymatically synthesized branched glucan used in the present invention is preferably about 2 x 105 or less, more preferably about 1 x 105 or less, still more preferably about 5 x 104 or less and most preferably about 3 x 104 10 or less.
[0073] In the present specification, the term "highly branched cyclic glucan" refers to a glucan having an internally branched cyclic structural moiety and an externally branched structural moiety and having a degree 15 of polymerization of 50 or more. The highly branched cyclic glucan may have at least two non-reducing ends as a whole molecule. The degree of polymerization of the highly branched cyclic glucan as a whole molecule that can be used in the present invention is preferably about 50 or more, 20 more preferably about 60 or more, and still more preferably about 100 or more. The degree of polymerization of the highly branched cyclic glucan as a whole molecule that can be used in the present invention is preferably about 1 x 104 or less, more preferably about 7 x 103 or less, and still more preferably about 5 x 103 25 or less.
[0074] The degree of polymerization of the internally branched cyclic structural moiety present in the highly branched cyclic glucan is preferably about 10 or more, more preferably about 15 or more, and further preferably about 30 20 or more. The degree of polymerization of the internally branched cyclic structural moiety present in the highly branched cyclic glucan is preferably about 500 or less, more preferably about 300 or less, and further preferably about EG037PCT 100 or less.
[0075] The degree of polymerization of the externally branched structural moiety present in the highly branched cyclic glucan is preferably about 40 or more, more preferably about 100 or more, further preferably 5 bly about 300 or more, and further more preferably about 500 or more. The degree of polymerization of the externally branched structural moiety present in the highly branched cyclic glucan is preferably about 3 x 103 or less, more preferably about 1 x 103 10 or less, further preferably about 500 or less, and further more preferably about 300 or less.
[0076] The number of -1,6-glucosidic bonds in the internally branched cyclic structural moiety present in the highly branched cyclic glucan may be at least one, and for 15 example, can be one or more, 5 or more, 10 or more or the like; the number of -1,6-glucosidic bonds in the internally branched cyclic structural moiety can be, for example, about 200 or less, about 50 or less, about 30 or less, about 15 or less, about 10 or less or the like. 20 The number of branches (that is, the number of -1,6-glucosidic bonds) in the externally branched structural moiety present in the highly branched cyclic glucan is preferably about 2 or more, more preferably about 3 or more, further preferably about 5 or more, and especially 25 preferably about 10 or more. The number of branches (that is, the number of -1,6-glucosidic bonds) in the externally branched structural moiety present in the highly branched cyclic glucan is preferably about 5 x 103 or less, more preferably about 4 x 103 or less, and further preferably about 3 x 103 30 or less.
[0077] As the highly branched cyclic glucan, a highly branched cyclic glucan having one kind of a degree of polymerization may be used alone, or a mixture of highly EG037PCT branched cyclic glucans having a variety of degree of polymerization may be used. Preferably, the degrees of polymerization of the highly branched cyclic glucan is such that the ratio of the degrees of polymerization of the maximum 5 degree of polymerization to the minimum degree of polymerization is about 100 or less, more preferably about 50 or less, and further more preferably about 10 or less.
[0078] The highly branched cyclic glucan is preferably a glucan having an internally branched cyclic structural moiety 10 and an externally branched structural moiety and having a degree of polymerization in a range of 50 to 5 x 103, wherein the internally branched cyclic structural moiety is a cyclic structural moiety formed with an -1,4-glucosidic bond and an -1,6-glucosidic bond, and the externally branched 15 structural moiety is a non-cyclic structural moiety bound to the internally branched cyclic structural moiety. The degree of polymerization of each unit chain of this externally branched structural moiety is, on average, preferably about 10 or more and preferably about 20 or less. The highly 20 branched cyclic glucan and a method for producing the same are described in detail in Japanese Laid-Open Publication No. 8-134104 (Japanese Patent No. 3107358), and this glucan can be produced according to the description of it. The highly branched cyclic glucan is commercially available, 25 for example, as "Cluster Dextrin" from Ezaki Glico Co., Ltd. The degree of polymerization of the highly branched cyclic glucan used in the present invention is preferably about 50 or more, more preferably about 70 or more, further preferably about 100 or more, most preferably about 150 or 30 more. The degree of polymerization of the highly branched cyclic glucan used in the present invention is preferably about 1 x 104 or less, more preferably about 7 x 103 or less, further preferably about 5 x 103 or less, and most preferably EG037PCT about 4 x 103 or less.
[0079] In a specific embodiment, the branched glucan can be particulate. It is known that particles having a diameter of about 4 nm or less are excreted from kidney, particles having a diameter of about 4 nm to about 200 nm are 5 circulated in blood for a long time, particles having a diameter of about 200 nm to about 7 m are captured by a reticuloendothelial system, and particles having a diameter of about 7 m or more obstruct capillary blood vessels. A 10 reticuloendothelial system is distributed in liver and spleen. For this reason, by controlling the particle size of the branched glucan, the pharmacokinetics of the amino sugar-containing glucan and a modified product thereof and a conjugate thereof of the present invention in vivo can 15 be controlled. When one intends to circulate the particles in blood for a long time, the particle size of a particulate branched glucan is, as the diameter, preferably about 4 nm or more, more preferably about 10 nm or more, preferably about 200 nm or less, and more preferably about 100 nm or 20 less. The molecular weight of the particulate branched glucan having such a particle size is preferably about 5 x 105 or more, more preferably about 1 x 106 or more, preferably about 5 x 107 or less, and more preferably about 2 x 107 or less. For example, since it is known that particles having 25 a diameter of 20 to 50 nm are accumulated in cancer cells, when it is intended that the particles are accumulated in cancer cells, the particle size of the particulate branched glucan is, as the diameter, preferably about 10 nm or more, more preferably about 15 nm or more, preferably about 100 30 nm or less, and more preferably about 50 nm or less. The molecular weight of the particulate branched glucan having such a particle size is preferably about 5 x 105 or more, more preferably about 1 x 106 or more, preferably about 2 EG037PCT x 107 or less, and more preferably about 5 x 106 or less.
[0080] The number of branches in the -glucan (i.e. the number of -1,6-glucosidic bonds) is preferably about 1 or more, more preferably about 10 or more, further preferably about 30 or more. The number of branches of the 5 -glucan (i.e. the number of -1,6-glucosidic bonds) is preferably about 5 x 103 or less, more preferably about 3 x 103 or less, further preferably about 1 x 103 or less.
[0081] In the branched -glucan used in the present 10 invention, the ratio of the number of -1,6-glucosidic bonds relative to the number of -1,4-glucosidic bonds ("number of -1,6-glucosidic bonds" : "number of -1,4-glucosidic bonds") is preferably 1 : 1 to 1 : 1 x 103, more preferably 1 : 1.1 to 1 : 500, further preferably 1 : 1.2 to 1 : 100, 15 further more preferably 1 : 1.5 to 1 : 50, and most preferably 1 : 2 to 1 : 20. The ratio may be, in some cases, 1 : 10 to 1 : 5 x 103, 1 : 50 to 1 : 1 x 103, or 1 : 100 to 1 : 500. In the present invention, the lower limit of the branching frequency of the branched glucan is preferably 0.2% or more, 20 preferably 1% or more, more preferably 2% or more, and most preferably 5% or more. While there is no specific upper limit of the branching frequency, it can be, for example, 99% or less, 90% or less, 85% or less, 65% or less, 50% or less, or the like. The branching frequency is calculated by 25 {(number of -1,6-bonds)/(sum of -1,4-bonds and -1,6-bonds in glucan)} x 100.
[0082] The -1,6-glucosidic bonds may be randomly distributed in the -glucan or may be homogeneously distributed in the -glucan. A distribution to such an extent 30 that a linear chain part(s) of 5 or more saccharide units can be formed in the -glucan is preferable.
[0083] In the present invention, a modified product of the glucan may be used in place of the glucan. Examples of the EG037PCT modified product of the glucan include a modified starch and an esterified product of the glucan explained above. Furthermore, the modified product of the glucan may be a hydroxyl group-modified product or a reducing end-modified product. In 5 addition, as described later, after at least one amino monosaccharide residue is -1,4-bound to each of at least one non-reducing end of the glucan, a glucan moiety may be modified.
[0084] The modified starch is a starch which was made to 10 have a nature that it is easier to use by subjecting a natural starch to treatment such as hydrolysis, esterification or gelatinization. Wide variety of modified starches having a variety of combinations of a gelatinization initiation temperature, a viscosity of a starch paste, a degree of 15 transparency of a starch paste, stability against retrogradation and the like are available. There are various types of modified starches. An example of such a starch is a starch obtained by immersing starch granules in an acid at a gelatinization temperature or lower of the starch, 20 thereby cutting a starch molecule but not destroying starch granules.
[0085] Examples of the modified product of the glucan other than the modified starch include a modified product in which at least one of alcoholic hydroxyl groups of an unmodified 25 glucan is modified (hereinafter, in the present specification, referred to as a "hydroxyl group-modified product of glucan"), a modified product in which some of non-reducing ends of the glucan is modified (hereinafter, in the present specification, referred to as a " non-reducing end-modified 30 product of glucan") and a modified product in which the reducing end of a glucan is modified (hereinafter, in the present specification, referred to as a "reducing end-modified product of glucan"). EG037PCT
[0086] Examples of the modification at a hydroxyl group include hydroxyalkylation, alkylation, acylation, carboxymethylation, sulfation and phosphorylation. It is preferable that modification at a hydroxyl group is a modification which can be removed with an enzyme in a 5 body. The hydroxyl group-modified product of the glucan is preferably an acylated glucan, and further preferably an acetylated glucan. The frequency of introduction of the modifying group(s) into alcoholic hydroxyl groups can be 10 arbitrarily set at the time of a modification reaction of the glucan. The frequency of introduction of the modifying group(s) into alcoholic hydroxyl groups is expressed as DS, and DS1 means the state where one modifying group per glucose residue is introduced. DS can be calculated by DS = (number 15 of modifying group)/(number of glucose residue). Since there is an OH group at the 2-position, the 3-position and the 6-position in an unmodified glucose residue, theoretically, maximum 3 modifying groups per glucose residue can be introduced. For this reason, the upper limit of DS 20 is usually 3. The frequency of introduction of the modifying group(s) into alcoholic hydroxyl groups is about DS 0.01 or more, more preferably about DS 0.03 or more, further preferably about DS 0.05 or more, particularly preferably about DS 0.07 or more, and most preferably about DS 0.1 or 25 more. The frequency of introduction of modifying group(s) is preferably about DS 1.5 or less, more preferably about DS 1.3 or less, further preferably about DS 1.1 or less, particularly preferably about DS 1.0 or less, and most preferably about DS 0.9 or less. By modifying the glucan, 30 degradation of the glucan in blood or in a body is suppressed.
[0087] Examples of modification at a non-reducing end include binding with a targeting molecule such as a mannose residue or a galactose residue. Modification at a EG037PCT non-reducing end will be explained in detail in the following 2.6 and 3 sections. A non-reducing end-modified product is preferably a conjugate with a mannose residue or a conjugate with a galactose residue. [5 0088] Examples of modification at a reducing end include binding with a substance selected from the group consisting of a monosaccharide, a non-reducing carbohydrate, a biocompatible macromolecule, a liposome constituent component, a glycoside and an amine group-containing 10 low-molecular weight substance. Modification at a non-reducing end will be explained in detail in the following 2.6 and 3 sections.
[0089] (1.2) Amino sugar Amino sugar is a generic name of sugars wherein at least 15 one hydroxyl group is replaced with an amino group. It is preferable that the sugar moiety of an amino sugar is a monosaccharide, and preferably a hexose. When the sugar moiety is a hexose, the number of amino groups in the amino sugar can be any integer of 1 to 4, preferably 1 or 2, and 20 most preferably 1. In the present invention, amino sugars wherein the hydroxyl group at the 2-position of the sugar is replaced with an amino group are preferable. Example of representative amino sugars includes glucosamine, galactosamine, and mannosamine. Glucosamine is the most 25 preferable as the amino sugar in the present invention. A plural kind of amino sugars may be used in mixed, or one kind of amino sugar may be used.
[0090] (2.Method for producing an amino sugar-containing glucan) 30 (2.1) Amino sugar-1-phosphate In the method of the present invention, amino sugar-1-phosphate can be used. Preferably, glucosamine-1-phosphate, galactosamine-1-phosphate or EG037PCT mannosamine-1-phosphate is used. The amino sugar-1-phosphate may be commercially available amino sugar-1-phosphate, or amino sugar-1-phosphate synthesized by a chemical method, an enzymatic method, or a biological method such as fermentation. The method for producing 5 g amino sugar-1-phosphate is known in the art. For example, a method for synthesizing glucosamine-1-phosphate is disclosed in, for example, Nawaji, et al., Carbohydr. Res. 2008, 343, 2692-2696. 10 [0091] As an amino sugar-1-phosphate, any of amino sugar-1-phosphate not in a salt form and amino sugar-1-phosphate in the form of a salt can be used. For example, as glucosamine-1-phosphate, any of glucosamine-1-phosphate not in a salt form and 15 glucosamine-1-phosphate in the form of a salt can be used. For example, a metal salt of glucosamine-1-phosphate can be used, and an alkali metal salt of glucosamine-1-phosphate (for example, disodium glucosamine-1-phosphate and dipotassium glucosamine-1-phosphate) can be used. 20 [0092] (2.2) -Glucan phosphorylase In the present specification, the term "-glucan phosphorylase" means an enzymes having -glucan phosphorylase activity. -Glucan phosphorylase is classified in EC 2.4.1.1. -Glucan phosphorylase activity 25 refers to an activity catalyzing a reaction producing glucose-1-phosphate and partial degraded products of an -1,4-glucan from inorganic phosphate and the -1,4-glucan, or the reverse reaction thereof. -Glucan phosphorylase can also catalyze an -1,4-glucan synthesizing reaction which 30 is the reverse reaction relative to phosphorolysis. In which direction a reaction proceeds depends on the amount of substrate.
[0093] In the present invention, any -glucan phosphorylase EG037PCT can be used as long as it has a function to transfer a glucosamine residue to a non-reducing end of glucan. -glucan phosphorylase used in the present invention can be derived from a bacterium, a yeast, an animal or a plant. -glucan phosphorylase 5 rylase of the present invention can be derived from, for example, potato, sweet potato, Fava bean, Arabidopsis thaliana, spinach, corn, rice, wheat, Citrus hybrid cultivar, Aquifex aeolicus, Thermotoga maritima, Thermococcus zilligii, Thermoanaerobacter pseudethanolicus, 10 or the like.
[0094] It is preferable that -glucan phosphorylase used in the present invention is -glucan phosphorylase derived from Aquifex aeolicus VF5. In a specific embodiment, potato-derived -glucan phosphorylase or Thermococcus 15 zilligii AN1-derived -glucan phosphorylase may be used.
[0095] The base sequence of -glucan phosphorylases derived from Aquifex aeolicus VF5 is set forth in SEQ ID NO: 1, and its amino acid sequence is set forth in positions 1-692 of SEQ ID NO: 2. The amino acid sequence of -glucan 20 phosphorylases derived from Aquifex aeolicus VF5 has about 21% to about 24 % sequence identity with the amino acid sequence of plant -glucan phosphorylases, about 34% sequence identity with the amino acid sequence of -glucan phosphorylases derived from Thermus thermophilus, and about 38% sequence 25 identity with the amino acid sequence of -glucan phosphorylases derived from Thermococcus litoralis. It has about 38% sequence identity with the amino acid sequence of -glucan phosphorylases derived from Thermotoga maritima, about 38% sequence identity with the amino acid sequence 30 of maltodextrin phosphorylases derived from Thermococcus zilligii, and about 33% sequence identity with those of Thermoanaerobacter pseudethanolicus.
[0096] The base sequence of type L -glucan phosphorylases EG037PCT derived from potato is set forth in SEQ ID NO: 3, and its amino acid sequence is set forth in positions 15-930 of SEQ ID NO: 4. The base sequence of -glucan phosphorylases derived from Thermococcus zilligii AN1 is set forth in SEQ ID NO: 5, and its amino acid sequence is set forth in 5 positions 1-717 of SEQ ID NO: 6.
[0097] In the present specification, an enzyme "derived from" an organism, means not only that the enzyme is directly isolated from the organism, but also refers to an enzyme 10 obtained by utilizing the organism in any form. For example, when a gene encoding an enzyme obtained from an organism is introduced into Escherichia coli, and the enzyme is isolated from that Escherichia coli, the enzyme is referred to as being "derived from" the organism. 15 [0098] In the present specification, "identity" of a sequence (for example, an amino acid sequence, a base sequence and the like) refers to the degree of occurrence of the same amino acid (base when base sequences are compared) between two sequences. Identity can be generally determined by 20 comparing two amino acid sequences or two base sequences, and comparing these two sequences which are aligned in an optimal format, which can contain additions or deletions.
[0099] In the present specification, the identity of sequences is calculated using maximum matching of GENETYX-WIN 25 Ver.4.0 (Genetics Co., Ltd.). This program aligns sequence data to be analyzed, and sequence data to be compared so that amino acid pairs matched between sequences become greatest while substitution and deletion are considered, and thereupon, gives a score to each of Matches, Mismatches, 30 and Gaps, calculates a sum, outputs alignment at the smallest sum, and calculates identity thereupon (Reference: Takeishi, K., and Gotoh, O. 1984. Sequence Relationships among Various 4.5 S RNA Species J. Biochem. 92:1173-1177). EG037PCT
[0100] For example, the amino acid sequence of -glucan phosphorylases used in the present invention can be same with SEQ ID NO: 2, 4 or 6, i.e., it can have 100% identity. In another embodiment, as long as having activity to transfer glucosamine residue to non-reducing 5 g end of a glucan, this amino acid sequence may be altered in up to a certain number of amino acids compared with a reference amino acid sequence. Such alterations can be selected from the group consisting of a deletion, a substitution (including conservative 10 substitution and non-conservative substitution), or an insertion of at least 1 (for example, 1 or several) amino acids. This alteration may occur at a position of an amino terminus or a carboxyl terminus of the amino acid sequence of SEQ ID NO: 2, 4 or 6, or may occur at any position other 15 than these termini. Alteration of an amino acid residue may be interspersed with one residue, or a few residues may be contiguous. For example, -glucan phosphorylases used in the present invention may be added with amino acid residues (preferably about 20 or less residues, more preferably about 20 10 or less residues, and further preferably about 5 or less residues) at either terminus of the amino acid sequence of SEQ ID NO: 2, 4 or 6, for the reasons such as to make ease of purification of the enzyme, to increase stability, or the like. 25 [0101] The -glucan phosphorylase used in the present invention has an amino acid sequence which has preferably about 50% or more, more preferably about 60% or more, further more preferably about 70% or more, still more preferably about 80% or more, particularly more preferably about 90% 30 or more, and most preferably about 95% or more sequence identity with the amino acid sequence of SEQ ID NO: 2, 4 or 6 and has an activity transferring a glucosamine residue to a non-reducing end of the glucan. The -glucan EG037PCT phosphorylase used in the present invention can have an amino acid sequence which has about 96 % or more, about 97% or more, about 98 % or more, or about 99 % more sequence identity with amino acid sequence of SEQ ID NO: 2, 4 or 6.
[0102] The amount of the -glucan phosphorylase 5 ylase contained in a solution at the start of the reaction is preferably about 0.01 U/ml or more, more preferably about 0.1 U/ml or more, particularly preferably about 0.5 U/ml or more, and most preferably about 1 U/ml or more. The amount of the 10 -glucan phosphorylase contained in a solution at the start of the reaction is preferably about 1,000 U/ml or less, more preferably about 100 U/ml or less, particularly preferably about 50 U/ml or less, and most preferably about 20 U/ml or less. If the weight of -glucan phosphorylase is too large, 15 it may became easy to aggregate the enzyme denatured during the reaction. If the amount used is too small, reaction itself occurred, but the yield of glucan may be lowered. It is noted that unit amount of -glucan phosphorylase is defined as follows: 20 Regarding one unit of -glucan phosphorylase, an -glucan phosphorylase activity which produces 1 mol inorganic phosphate (Pi) per one minute shall be one unit (U or Unit). This measurement of -glucan phosphorylase activity quantitates free inorganic phosphate (Pi) produced from G-1-P. 25 After 200 l of a reaction solution (containing 12.5 mM G-1-P, 1% dextrin and an enzyme solution in a 100 mM acetate buffer (pH 6.0)) is incubated at 50°C for 15 minutes, 800 l of a molybdenum regent (15 mM ammonium molybdate, 100 mM zinc acetate) is added, and this is stirred to stop the reaction. 30 200 l of 568 mM ascorbic acid (pH 5.8) is added, followed by mixing. After incubation at 30°C for 15 minutes, an absorbance is measured at 850 nm using a spectrophotometer. An absorbance is measured similarly using inorganic phosphate EG037PCT having the known concentration, and a standard curve is produced. An absorbance value obtained for a sample is fitted to this standard curve, and the amount of inorganic phosphate in the sample is determined. Inorganic phosphate is quantitated as a phosphoric acid ion. The 5 amount of glucose-1-phosphate is not quantitated.
[0103] (2.3 Production of -glucan phosphorylase) -Glucan phosphorylase used in the present invention can be directly isolated from an organism producing -glucan 10 phosphorylase, such as the aforementioned organisms, present in the natural world. Alternatively, -glucan phosphorylase used in the present invention may be isolated from a microorganism (for example, bacteria, fungi and the like) which has been genetically modified with a gene encoding 15 -glucan phosphorylase isolated from the aforementioned organism.
[0104] In a preferred embodiment, -glucan phosphorylase derived from Aquifex aeolicus VF5 is produced by chemically synthesizing a gene fragment of SEQ ID NO: 1, constructing 20 an expression vector containing this gene fragment, introducing this expression vector into a microorganism to make a recombinant microorganism, culturing this recombinant microorganism to produce -glucan phosphorylase, and collecting produced -glucan phosphorylase. -glucan 25 phosphorylase derived from other organism can also be produced as well. An enzymatic production method by gene recombination is well-known to those skilled in the art. A host microorganism used in the present invention includes a prokaryote and a eukaryote, and a mesophile is preferable. 30 Examples of a particularly preferred microorganism include, but not limited to, Escherichia coli.
CLAIMS Claim 1. A glucosamine-containing branched glucan, wherein the glucan has a plurality of non-reducing ends and at least one glucosamine residue is bound via an 5 -1,4-bond to each of two or more non-reducing ends of the branched -1,4-glucan, but no glucosamine residue is present at the position other than the non-reducing ends of the branched -1,4-glucan, and the degree of polymerization of the branched -1,4-glucan is 15 or more and 4 x 105 10 or less. Claim 2. The glucosamine-containing branched glucan according to claim 1, wherein the branched -1,4-glucan is selected from the group consisting of a branched 15 maltooligosaccharide, a starch, amylopectin, glycogen, dextrin, enzymatically synthesized branched glucan and highly branched cyclic glucan. Claim 3. A hydroxyl group-modified product of the 20 glucosamine-containing branched glucan according to claim 1, wherein the modification on the hydroxyl group is a modification on some or all of alcoholic hydroxyl groups of the glucan, and the modification on the hydroxyl group is independently selected from the group consisting of 25 hydroxyalkylation, alkylation, acetylation, carboxymethylation, sulfation and phosphorylation. Claim 4. A reducing end-modified product of the glucosamine-containing branched glucan according to claim 30 1 or a hydroxyl group-modified product thereof. Claim 5. An amino group-modified product of the glucosamine-containing branched glucan according to claim EG037PCT 1, a hydroxyl group-modified product thereof or a reducing end-modified product thereof, wherein the modification on the amino group is a modification on some or all of amino groups of the glucosamine residues, the modification on the amino group is attained by a reaction 5 ion of the amino group and an amino group-modifying reagent, and the amino group-modifying reagent has at least one carboxyl group and at least one other functional group. 10 Claim 6. A non-reducing end-modified product of the glucosamine-containing branched glucan according to claim 1, a hydroxyl group-modified product thereof, a reducing end-modified product thereof or an amino group-modified product thereof, wherein a targeting molecule is bound to 15 at least one of non-reducing ends to which the glucosamine residue of the branched glucan is not bound, wherein the targeting molecule is selected from the group consisting of mannose, galactose, glucuronic acid, N-acetylglucosamine, xylose, fucose, galactosamine, an antibody, an antibody 20 fragment, a receptor, a receptor fragment and a receptor ligand. Claim 7. A method for producing a glucosamine-containing branched glucan, characterized by allowing an -glucan 25 phosphorylase to act on an aqueous solution comprising a branched -1,4-glucan and glucosamine-1-phosphate, wherein the degree of polymerization of the branched -1,4-glucan is 15 or more and 4 x 105 or less. 30 Claim 8. The method according to claim 7, wherein the -glucan phosphorylase has 95% or more sequence identity with the amino acid sequence of -glucan phosphorylase derived from Aquifex aeolicus VF5, and has activity of EG037PCT transferring glucosamine to a non-reducing end of a branched glucan to form an -1,4-bond. Claim 9. A medicament comprising the glucosamine-5 containing branched glucan according to claim 1, a hydroxyl group-modified product thereof, a reducing end-modified product thereof, an amino group-modified product thereof, or a non-reducing end-modified product thereof, and a medically effective ingredient. 10 Claim 10. The medicament according to claim 9, wherein the medically effective ingredient is selected from the group consisting of a low-molecular weight organic compound, a protein, a peptide, an antibody, an antibody fragment, a 15 receptor, a receptor fragment, a DNA, an RNA, a siRNA, an miRNA and an RNA aptamer. Claim 11. A composition for clinical diagnosis comprising the glucosamine-containing branched glucan according to 20 claim 1, a hydroxyl group-modified product thereof, a reducing end-modified product thereof, an amino group-modified product thereof, or a non-reducing end-modified product thereof. 25 Claim 12. A nanoparticulate carrier for a DDS comprising the glucosamine-containing branched glucan according to claim 1, a hydroxyl group-modified product thereof, a reducing end-modified product thereof, an amino group-modified product thereof, or a non-reducing 30 end-modified product thereof. Claim 13. The carrier according to claim 12, wherein the nanoparticulate carrier for a DDS is selected from the group EG037PCT consisting of a liposome, a virus particle, a macromolecule micelle and a nanogel composed of macromolecule bearing hydrophobic groups. Claim 14. A 5 complex formed with a nucleic acid molecule and the glucosamine-containing branched glucan according to claim 1. Claim 15. The complex according to claim 14, wherein the 10 nucleic acid molecule is selected from the group consisting of a DNA, an RNA, a siRNA, an miRNA and an RNA aptamer. Claim 16. A complex formed with the complex carrier according to claim 14, and a cationic polymer or a cationic lipid. 15 Claim 17. The complex according to claim 16, wherein the cationic polymer comprises at least one cationic polymer selected from the group consisting of polyethyleneimine, polylysine, polyarginine, polyamidoamine dendrimer, 20 poly(aminostyrene), chitosan, a cationic glucan and DEAE-dextran. Claim 18. A method for delivering a nucleic acid molecule into an isolated cell, comprising contacting the complex 25 according to claim 14 with the cell.